Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Anemia 5Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia 3Thrombocytopenia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Paraproteinemias 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1Fever 1Fatigue 1Anemia, Refractory 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 30fludarabine phosphate 25Cyclosporine 25Busulfan 20Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Cord Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Whole-Body Irradiation 15Radiotherapy 15Methotrexate 12Methylprednisolone 10Filgrastim 10Cytarabine 8Etoposide 7Tacrolimus 6Melphalan 6sargramostim 5fludarabine 4Thiotepa 4Granulocyte Colony-Stimulating Factor 4Decitabine 4Cyclosporins 4Azacitidine 4merphos 3Transplantation 3Arsenic Trioxide 3bryostatin 1 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × Lenalidomide × Classical hematology × Clear all
NCT00104962 2014-06-11

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
Classical hematology

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡